Aptevo Therapeutics Inc
APVO2.600USD
-0.080-3.00%
시장 운영 시간 （ET）시세는 15분 지연됩니다
3.79M시가총액
손실P/E TTM
자세한 내용은 Aptevo Therapeutics Inc 회사
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
회사 정보
종목 코드 APVO
회사 이름Aptevo Therapeutics Inc
상장일Jul 20, 2016
CEOMr. Marvin L. White
직원 수37
유형Ordinary Share
회계 연도 종료Jul 20
주소2401 4th Ave Ste 1050
도시SEATTLE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호98121-3460
전화12068380500
웹사이트https://aptevotherapeutics.com/
종목 코드 APVO
상장일Jul 20, 2016
CEOMr. Marvin L. White
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
43.00
+30.30%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.00
+27.78%
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
1.00
--
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
1.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 23
마지막 업데이트: Wed, Jul 23
주주
주주 유형
주주
주주
비율
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
주주
주주
비율
Schiketanz Capital Advisors GmbH
0.02%
Geode Capital Management, L.L.C.
0.02%
Other
99.96%
주주 유형
주주
비율
Investment Advisor
0.02%
Investment Advisor/Hedge Fund
0.02%
Research Firm
0.01%
Other
99.95%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
37
1.61K
0.06%
-24.39K
2025Q1
50
1.38K
0.06%
-4.41K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Schiketanz Capital Advisors GmbH
290.00
0.01%
+290.00
--
Jan 31, 2025
Geode Capital Management, L.L.C.
526.00
0.02%
+526.00
--
Mar 31, 2025
Tower Research Capital LLC
163.00
0.01%
+109.00
+201.85%
Mar 31, 2025
Clear Street LLC
140.00
0%
+140.00
--
Mar 31, 2025
BofA Global Research (US)
116.00
0%
+116.00
--
Mar 31, 2025
White (Marvin L)
3.00
0%
+1.00
+50.00%
Apr 04, 2025
SBI Securities Co., Ltd.
35.00
0%
+28.00
+400.00%
Mar 31, 2025
Lamothe (Jeffrey G)
2.00
0%
--
--
Apr 04, 2025
Kwon (SoYoung)
1.00
0%
--
--
Apr 04, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
날짜
유형
비율
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
더 보기
